HCM
IBRX icon

Heights Capital Management’s ImmunityBio IBRX Stock Holding History

Heights Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,565,709
Closed -$16.2M – 201
2025
Q3 		$16.2M Buy
+6,565,709
New +$16.9M 4.6% 3

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Heights Capital Management's IBRX Position: Q4 2025 in Review

Heights Capital Management sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 6,565,709 shares — an estimated $16.2M sold.

Heights Capital Management first reported a position in IBRX in Q3 2025 and held it in 1 quarter. The position peaked at $16.2M in Q3 2025. 276 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

  • Heights Capital Management reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
  • Heights Capital Management sold 6,565,709 ImmunityBio shares in Q4 2025, an estimated $16.2M.
  • Heights Capital Management first reported a position in ImmunityBio in Q3 2025 and held it in 1 quarter.
  • Heights Capital Management's ImmunityBio position peaked at $16.2M in Q3 2025.
  • 276 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on Heights Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.